AWM Investment Company Inc. Makes New Investment in Neuronetics, Inc. $STIM

Key Points

• AWM Investment Company Inc. acquired 245,924 shares of Neuronetics, valued at approximately $905,000, marking a significant investment for the firm in the first quarter.
• Neuronetics reported a loss of ($0.15) earnings per share, missing analyst expectations, with a negative net margin of 43.47% during the last quarter.
• Analysts maintain a consensus "Buy" rating for Neuronetics, with an adjusted price target of $7.00 as per Canaccord Genuity Group's recent report.

AWM Investment Company Inc. bought a new stake in Neuronetics, Inc. (NASDAQ:STIM - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 245,924 shares of the company's stock, valued at approximately $905,000. AWM Investment Company Inc. owned approximately 0.37% of Neuronetics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in STIM. Ghisallo Capital Management LLC acquired a new stake in shares of Neuronetics during the first quarter worth $1,472,000. Balyasny Asset Management L.P. boosted its holdings in Neuronetics by 29.5% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock worth $2,386,000 after purchasing an additional 337,539 shares during the last quarter. CenterBook Partners LP purchased a new position in Neuronetics during the first quarter worth about $1,200,000. Cubist Systematic Strategies LLC purchased a new position in Neuronetics during the first quarter worth about $1,055,000. Finally, Walleye Capital LLC bought a new stake in Neuronetics in the first quarter worth about $892,000. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Canaccord Genuity Group lowered their price objective on shares of Neuronetics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, Neuronetics currently has an average rating of "Buy" and a consensus price target of $7.00.

Neuronetics Price Performance

STIM stock traded down $0.08 during midday trading on Friday, reaching $3.23. The company had a trading volume of 1,891,477 shares, compared to its average volume of 1,369,657. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.02 and a quick ratio of 1.84. Neuronetics, Inc. has a 1 year low of $0.52 and a 1 year high of $5.92. The company has a market capitalization of $213.57 million, a P/E ratio of -2.86 and a beta of 1.28. The firm has a 50-day moving average price of $3.74 and a 200-day moving average price of $3.99.

Neuronetics (NASDAQ:STIM - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.07). Neuronetics had a negative return on equity of 156.36% and a negative net margin of 43.47%.The company had revenue of $38.11 million during the quarter, compared to analysts' expectations of $36.80 million. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts anticipate that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.